[Skip to Content]
[Skip to Content Landing]
Other Articles
July 6, 1940


JAMA. 1940;115(1):47-48. doi:10.1001/jama.1940.02810270049013

In last week's issue of The Journal appeared three papers on the treatment of Addison's disease and a statement by Dr. E. S. Gordon1 on the therapeutic status of desoxycorticosterone acetate published under the auspices of the Council on Pharmacy and Chemistry. Our knowledge of the effectiveness of this substance and the possible dangers from indiscriminate use were clearly defined. Recently the Schering Corporation, one of the manufacturers of desoxycorticosterone acetate (Cortate), has been conducting an active advertising campaign to promote the use of this substance in the prevention and treatment of surgical shock. The arguments used seem subtle. In addition to the usual selection of the favorable references in the literature, the firm has supplied physicians with blank charts entitled "Cortate Routine" on which is presented a convenient form with specific directions for the ordering of Cortate (desoxycorticosterone acetate) preoperatively and postoperatively. Actually the clinical evidence to support